Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This is a comparative study of vonoprazan (TAK-438) (10 mg or 20 mg) in participants in whom
endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate
treatment with a proton pump inhibitor (PPI), to demonstrate the non-inferiority of
vonoprazan to lansoprazole in their maintenance treatment (6 months or 24 weeks) as well as
to determine the clinically recommended dose for vonoprazan for maintenance therapy in
erosive esophagitis.